BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 16279770)

  • 1. Novel tetralone-derived retinoic acid metabolism blocking agents: synthesis and in vitro evaluation with liver microsomal and MCF-7 CYP26A1 cell assays.
    Yee SW; Jarno L; Gomaa MS; Elford C; Ooi LL; Coogan MP; McClelland R; Nicholson RI; Evans BA; Brancale A; Simons C
    J Med Chem; 2005 Nov; 48(23):7123-31. PubMed ID: 16279770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and CYP24 inhibitory activity of 2-substituted-3,4-dihydro-2H-naphthalen-1-one (tetralone) derivatives.
    Yee SW; Simons C
    Bioorg Med Chem Lett; 2004 Nov; 14(22):5651-4. PubMed ID: 15482941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and CYP26A1 inhibitory activity of 1-[benzofuran-2-yl-(4-alkyl/aryl-phenyl)-methyl]-1H-triazoles.
    Pautus S; Yee SW; Jayne M; Coogan MP; Simons C
    Bioorg Med Chem; 2006 Jun; 14(11):3643-53. PubMed ID: 16458519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel retinoic acid metabolism blocking agents endowed with multiple biological activities are efficient growth inhibitors of human breast and prostate cancer cells in vitro and a human breast tumor xenograft in nude mice.
    Patel JB; Huynh CK; Handratta VD; Gediya LK; Brodie AM; Goloubeva OG; Clement OO; Nanne IP; Soprano DR; Njar VC
    J Med Chem; 2004 Dec; 47(27):6716-29. PubMed ID: 15615521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and biological evaluation of 3-(1H-imidazol- and triazol-1-yl)-2,2-dimethyl-3-[4-(naphthalen-2-ylamino)phenyl]propyl derivatives as small molecule inhibitors of retinoic acid 4-hydroxylase (CYP26).
    Gomaa MS; Bridgens CE; Veal GJ; Redfern CP; Brancale A; Armstrong JL; Simons C
    J Med Chem; 2011 Oct; 54(19):6803-11. PubMed ID: 21838328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular recognition of CYP26A1 binding pockets and structure-activity relationship studies for design of potent and selective retinoic acid metabolism blocking agents.
    Sun B; Song S; Hao CZ; Huang WX; Liu CC; Xie HL; Lin B; Cheng MS; Zhao DM
    J Mol Graph Model; 2015 Mar; 56():10-9. PubMed ID: 25541526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Substrate specificity and ligand interactions of CYP26A1, the human liver retinoic acid hydroxylase.
    Thatcher JE; Buttrick B; Shaffer SA; Shimshoni JA; Goodlett DR; Nelson WL; Isoherranen N
    Mol Pharmacol; 2011 Aug; 80(2):228-39. PubMed ID: 21521770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and CYP24A1 inhibitory activity of (E)-2-(2-substituted benzylidene)- and 2-(2-substituted benzyl)-6-methoxy-tetralones.
    Aboraia AS; Makowski B; Bahja A; Prosser D; Brancale A; Jones G; Simons C
    Eur J Med Chem; 2010 Oct; 45(10):4427-34. PubMed ID: 20655626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved Homology Model of the Human all-trans Retinoic Acid Metabolizing Enzyme CYP26A1.
    Awadalla MK; Alshammari TM; Eriksson LA; Saenz-Méndez P
    Molecules; 2016 Mar; 21(3):351. PubMed ID: 26999080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small molecule inhibitors of retinoic acid 4-hydroxylase (CYP26): synthesis and biological evaluation of imidazole methyl 3-(4-(aryl-2-ylamino)phenyl)propanoates.
    Gomaa MS; Bridgens CE; Aboraia AS; Veal GJ; Redfern CP; Brancale A; Armstrong JL; Simons C
    J Med Chem; 2011 Apr; 54(8):2778-91. PubMed ID: 21428449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis, and biological evaluation of amide imidazole derivatives as novel metabolic enzyme CYP26A1 inhibitors.
    Sun B; Liu K; Han J; Zhao LY; Su X; Lin B; Zhao DM; Cheng MS
    Bioorg Med Chem; 2015 Oct; 23(20):6763-73. PubMed ID: 26365710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and CYP26A1 inhibitory activity of novel methyl 3-[4-(arylamino)phenyl]-3-(azole)-2,2-dimethylpropanoates.
    Gomaa MS; Lim AS; Lau SC; Watts AM; Illingworth NA; Bridgens CE; Veal GJ; Redfern CP; Brancale A; Armstrong JL; Simons C
    Bioorg Med Chem; 2012 Oct; 20(20):6080-8. PubMed ID: 22989911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel azolyl-(phenylmethyl)]aryl/heteroarylamines: potent CYP26 inhibitors and enhancers of all-trans retinoic acid activity in neuroblastoma cells.
    Gomaa MS; Armstrong JL; Bobillon B; Veal GJ; Brancale A; Redfern CP; Simons C
    Bioorg Med Chem; 2008 Sep; 16(17):8301-13. PubMed ID: 18722776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Homology models of human all-trans retinoic acid metabolizing enzymes CYP26B1 and CYP26B1 spliced variant.
    Saenz-Méndez P; Elmabsout AA; Sävenstrand H; Awadalla MK; Strid Å; Sirsjö A; Eriksson LA
    J Chem Inf Model; 2012 Oct; 52(10):2631-7. PubMed ID: 22985482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of CYP26A1 by metabolites of retinoic acid: evidence that CYP26A1 is an important enzyme in the elimination of active retinoids.
    Topletz AR; Tripathy S; Foti RS; Shimshoni JA; Nelson WL; Isoherranen N
    Mol Pharmacol; 2015; 87(3):430-41. PubMed ID: 25492813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Synthesis and Evaluation of C7-Substituted α-Tetralone Derivatives as Inhibitors of Monoamine Oxidase.
    Legoabe LJ; Petzer A; Petzer JP
    Chem Biol Drug Des; 2015 Oct; 86(4):895-904. PubMed ID: 25581511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Some 1,2-diphenylethane derivatives as inhibitors of retinoic acid--metabolising enzymes.
    Greer VP; Mason P; Kirby AJ; Smith HJ; Nicholls PJ; Simons C
    J Enzyme Inhib Med Chem; 2003 Oct; 18(5):431-43. PubMed ID: 14692511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the ligand binding site of CYP2C8 with CYP26A1 and CYP26B1: a structural basis for the identification of new inhibitors of the retinoic acid hydroxylases.
    Foti RS; Diaz P; Douguet D
    J Enzyme Inhib Med Chem; 2016; 31(sup2):148-161. PubMed ID: 27424662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and Characterization of Novel and Selective Inhibitors of Cytochrome P450 CYP26A1, the Human Liver Retinoic Acid Hydroxylase.
    Diaz P; Huang W; Keyari CM; Buttrick B; Price L; Guilloteau N; Tripathy S; Sperandio VG; Fronczek FR; Astruc-Diaz F; Isoherranen N
    J Med Chem; 2016 Mar; 59(6):2579-95. PubMed ID: 26918322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Homology model of human retinoic acid metabolising enzyme cytochrome P450 26A1 (CYP26A1): active site architecture and ligand binding.
    Gomaa MS; Yee SW; Milbourne CE; Barbera MC; Simons C; Brancale A
    J Enzyme Inhib Med Chem; 2006 Aug; 21(4):361-9. PubMed ID: 17059167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.